A. “Linking Protective GAB2 Variants, Increased Cortical GAB2 Expression and Decreased Alzheimer’s Disease Pathology,” by Fanggeng Zou, Olivia Belbin, Minerva M. Carrasquillo, Oliver J. Culley, Talisha A. Hunter, Li Ma, Gina D. Bisceglio, Mariet Allen, Dennis W. Dickson, Neill R. Graff-Radford, Ronald C. Petersen, the Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) Consortium, Kevin Morgan, and Steven G. Younkin (PLoS ONE 8(5): e64802. doi:10.1371/journal.pone.0064802, XML, HTML, and .pdf format, 11p.).
www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0064802
B. “Comparison of Treatment Effect Estimates for Pharmacological Randomized Controlled Trials Enrolling Older Adults Only and Those including Adults: A Meta-Epidemiological Study,” by Valerie Seegers, Ludovic Trinquart, Isabelle Boutron, and Philippe Ravaud (PLoS ONE 8(5): e63677. doi:10.1371/journal.pone.0063677, HTML, XML, and .pdf format, 5p.).
www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0063677
